Literature DB >> 4108576

Serum concentration and urinary excretion of 3 H-ouabain and 3 H-digitoxin in patients suffering from hyperthyroidism or hypothyroidism.

W Eickenbusch, H Lahrtz, U Seppelt, P A van Zwieten.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1970        PMID： 4108576     DOI： 10.1007/bf01486435

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN： 0023-2173


× No keyword cloud information.
  17 in total

1.  STUDIES WITH TRITIATED DIGOXIN IN RENAL FAILURE.

Authors:  J E DOHERTY; W H PERKINS; M C WILSON
Journal:  Am J Med       Date:  1964-10       Impact factor: 4.965

2.  DISTRIBUTION IN PLASMA, UPTAKE BY THE HEART AND EXCRETION OF OUABAIN-H3 IN HUMAN SUBJECTS.

Authors:  B H MARKS; S DUTTA; J GAUTHIER; D ELLIOTT
Journal:  J Pharmacol Exp Ther       Date:  1964-09       Impact factor: 4.030

3.  Metabolic fate of radioactive digitoxin in human subjects.

Authors:  G T OKITA; P J TALSO; J H CURRY; F D SMITH; E M GEILING
Journal:  J Pharmacol Exp Ther       Date:  1955-12       Impact factor: 4.030

4.  [Not Available].

Authors:  W DOERR; K HOLLDACK
Journal:  Virchows Arch Pathol Anat Physiol Klin Med       Date:  1948

5.  [On the characteristics of the binding of cardiac glycosides by plasma proteins].

Authors:  K Kuschinsky
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1969

6.  [Serum concentration and excretion of H3Y digitoxin in humans under normal and pathologic conditions].

Authors:  H Lahrtz; H M Reinold; P A van Zwieten
Journal:  Klin Wochenschr       Date:  1969-07-01

7.  The influence of kidney or liver disorders on the serum concentration and urinary excretion of 3H-peruvoside, a tritium-labelled cardiac glycoside.

Authors:  H Lahrtz; P A van Zwieten
Journal:  Eur J Pharmacol       Date:  1968-05       Impact factor: 4.432

8.  Studies with tritiated digoxin in anephric human subjects.

Authors:  J E Doherty; W J Flanigan; W H Perkins; G L Ackerman
Journal:  Circulation       Date:  1967-02       Impact factor: 29.690

9.  [On the tissue distribution, metabolism and excretion of cardiac glycosides].

Authors:  P A van Zwieten
Journal:  Dtsch Med Wochenschr       Date:  1967-09-15       Impact factor: 0.628

10.  The metabolism of tritiated digoxin in renal insufficiency in dogs and man.

Authors:  F I Marcus; A Peterson; A Salel; J Scully; G G Kapadia
Journal:  J Pharmacol Exp Ther       Date:  1966-06       Impact factor: 4.030
View more
  9 in total

Review 1.  Influence of thyroid dysfunction on drug pharmacokinetics.

Authors:  G M Shenfield
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

2.  Serum digoxin in patients with thyroid disease.

Authors:  M S Croxson; H K Ibbertson
Journal:  Br Med J       Date:  1975-09-06

Review 3.  Disease-related alterations in cardiac glycoside disposition.

Authors:  H R Ochs; D J Greenblatt; G Bodem; H J Dengler
Journal:  Clin Pharmacokinet       Date:  1982 Sep-Oct       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics and endocrine disorders. Therapeutic implications.

Authors:  P O'Connor; J Feely
Journal:  Clin Pharmacokinet       Date:  1987-12       Impact factor: 6.447

Review 5.  Digitalis pharmacokinetics and therapy with respect to impaired renal function.

Authors:  P Kramer
Journal:  Klin Wochenschr       Date:  1977-01-01

6.  Plasma and urinary digoxin in thyroid dysfunction.

Authors:  G M Shenfield; J Thompson; D B Horn
Journal:  Eur J Clin Pharmacol       Date:  1977-12-28       Impact factor: 2.953

Review 7.  Drug metabolism in thyroid disease.

Authors:  M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

8.  Ouabain-specific antibodies: immunochemical properties and reversal of Na + , K + -activated adenosine triphosphatase inhibition.

Authors:  T W Smith
Journal:  J Clin Invest       Date:  1972-06       Impact factor: 14.808

9.  Effects of thyroid hormone on sodium pump sites, sodium content, and contractile responses to cardiac glycosides in cultured chick ventricular cells.

Authors:  D Kim; T W Smith
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.